Search details
1.
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
J Clin Oncol
; 27(27): 4522-9, 2009 Sep 20.
Article
in English
| MEDLINE | ID: mdl-19687336
Results
1 -
1
de 1
1
Next >
>>